- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03104283
Apatinib for the Elderly Advanced Gastric Cancer
A Multicenter, Single-arm, Phase Ⅱ Clinical Trial of Apatinib Monotherapy in Elderly Patients With Advanced Gastric Cancer(GC)
Studieoversikt
Detaljert beskrivelse
The trial is funded by Chinese Society of Clinical Oncology-Beijing Xisike Clinical Oncology Research Fundation. The trial is prepared to be registered on the clinicaltrail.gov.
Quality assurance plan: Every participant is enrolled or excluded by two practiced investigators. And two investigators participate in all steps of the trail, including the record of the data, which is compared by the investigators. If the data is consistent, the investigators would record the data; if not, the data would be checked and decided by the two investigators. All the steps and data are site monitored and audited by the staff of research and financial department of Affliated Hospital of Qinghai University.
Data check: The investigators compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry.
Source data verification: The investigators assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources, including medical records and electronic case report forms.
Data dictionary that contains detailed descriptions of each variable used by the registry, including the source of the variable, coding information, and normal ranges if relevant.
Standard Operating Procedures to address registry operations and analysis activities, such as participants recruitment, data collection, data management, data analysis, reporting for adverse events, and change management. All registry operations would be done according to specific steps, and by two practiced investigators.
Sample size assessment to specify the number of participants or participant years necessary to demonstrate an effect. According to the formula to differ advantages and disadvantages, the investigators need at least 47 participants to take part in the trail. The investigators can recruit about 20 participants every year according to previous experiences, so the investigators should recruit about two years.
Plan for missing data: The investigators would collect as much data as possible, and the investigators exclude the participants who cannot cooperate on recruitment. And the investigators manage situations according to statistical principles where variables are reported as missing, unavailable, non-reported, uninterpretable, or considered missing because of data inconsistency or out-of-range results.
Statistical analysis plan: Statistical analyses would be performed by using SPSS software, version 13.0 (SPSS Inc., IL, USA). Survival analysis would be performed using Kaplan-Meier methodology. Fisher's exact test would be used to analyze the efficacy of treatment. Cox proportional hazards model would be used for multivariate analysis. The level of significance is defined as P < 0.05.
Studietype
Registrering (Faktiske)
Fase
- Fase 2
Kontakter og plasseringer
Studiesteder
-
-
Qinghai
-
Xining, Qinghai, Kina, 810000
- Affiliated Hospital of Qinghai University
-
Xining, Qinghai, Kina, 810000
- People's Hospital of Qinghai Province
-
Xining, Qinghai, Kina, 810000
- Qinghai Red Cross Hospital
-
Xining, Qinghai, Kina, 810000
- The Fifth People's Hospital of Qinghai Province
-
-
Shanxi
-
Yangquan, Shanxi, Kina, 045000
- Yangquan No.1 People's Hospital
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Elderly patients (aged ≥ 60 years) with histologically confirmed advanced adenocarcinoma of the stomach or gastroesophageal junction;
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
- Progression with or intolerance to one or more lines of chemotherapy;
- At least one measurable lesion as defined by RECIST 1.1;
- With acceptable hematologic, cardiac, hepatic, pulmonary and renal function;
- Can take apatinib orally;
- Estimated life expectancy ≥ 3 months.
Exclusion Criteria:
- Patients cannot take apatinib orally for any reason;
- Patients with uncontrolled central nervous system (CNS) metastases;
- Patients with massive hydrothorax or ascites;
- Proteinuria 2+ or 24-hour urinary protein ≥ 1g;
- Newly-happened traumatism or pathological fracture;
- Estimated life expectancy ˂ 3 months;
- Received chemotherapy in the past 28 days before enrollment;
- Patients with uncontrolled blood pressure on medication (≥ 140/90 mmHg);
- Patients with bleeding tendency, receiving thrombolytics or anticoagulants, receiving intravenous antibiotic treatment, had received bevacizumab or other VEGF TKIs before, or with other primary malignancy (except basal cell skin cancer or cervical carcinoma in situ).
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: N/A
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Apatinib Group
take apatinib orally (500mg/d or 250mg/d, once a day, continuously )
|
take apatinib orally until disease progression or appearance of unbearable toxicity
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Progression-free survival (PFS)
Tidsramme: 1 year
|
PFS was defined to be the time from registration to the date of disease progress sion or death resulting from any cause.
|
1 year
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Objective response rate (ORR)
Tidsramme: 1 year
|
ORR was defined as the proportion of eligible patients who achieved a confirmed complete response(CR )or partial response (PR) by RECIST 1.1 criteria evaluated by the investigators.
|
1 year
|
|
Disease control rate (DCR)
Tidsramme: 1 year
|
DCR was defined as the proportion of patients who achieved CR, PR and stable disease (SD) for at least 8 weeks.
|
1 year
|
|
Overall survival (OS)
Tidsramme: 1 year
|
OS was defined to be the time from registration to the date of death resulting from any cause or the last follow-up visit.
|
1 year
|
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
- Sykdommer i fordøyelsessystemet
- Neoplasmer
- Neoplasmer etter nettsted
- Gastrointestinale neoplasmer
- Neoplasmer i fordøyelsessystemet
- Gastrointestinale sykdommer
- Magesykdommer
- Neoplasmer i magen
- Molekylære mekanismer for farmakologisk virkning
- Enzymhemmere
- Antineoplastiske midler
- Proteinkinasehemmere
- Apatinib
Andre studie-ID-numre
- AHQU-2017001
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Magekreft
-
Washington University School of MedicineNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)FullførtRoux-en-Y Gastric Bypass | Bariatrisk kirurgi | Vertical Sleeve Gastrectomy | Magebånd | Bypass, GastricForente stater
-
Medtronic - MITGFullført
-
North Dakota State UniversityNational Institutes of Health (NIH)FullførtRoux en Y Gastric Bypass kirurgiForente stater
-
Jessa HospitalHar ikke rekruttert ennå
-
Wageningen UniversityRijnstate HospitalUkjentRoux-en-Y Gastric BypassNederland
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaFullførtRoux en Y Gastric BypassForente stater
-
DuomedAktiv, ikke rekrutterendeOvervekt | Gastrectomi | Roux-en-Y Gastric Bypass | Mini Gastric BypassBelgia
-
Olympus Corporation of the AmericasUnity Health TorontoFullført
-
GCS Ramsay Santé pour l'Enseignement et la RechercheEuraxi PharmaRekrutteringBypass, GastricFrankrike
-
North Dakota State UniversityNeuropsychiatric Research Institute, Fargo, North DakotaFullførtSleeve Gastrectomy | Roux en Y Gastric BypassForente stater
Kliniske studier på Apatinib
-
Song PengHar ikke rekruttert ennåHepatocellulært karsinom Ikke-resektabeltKina
-
Linhui PengRekrutteringHepatocellulært karsinom (HCC) | Kjemoterapi effektKina
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Har ikke rekruttert ennå
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Har ikke rekruttert ennåHepatocellulært karsinom (HCC) | Ikke-opererbart hepatocellulært karsinom (HCC) | Leverkreft VoksenKina
-
Beijing Friendship HospitalRekrutteringAdenokarsinom i magen | Adenokarsinom av GE Junction | AdebrelimabKina
-
The First Affiliated Hospital of Zhengzhou UniversityRekrutteringAvansert magekreft | SHR1701Kina
-
First Affiliated Hospital of Chongqing Medical...Har ikke rekruttert ennåImmunmodulering | Hepatocellulære karsinomer | Motstand mot immunterapi | LegemiddelgjenbrukKina
-
Fujian Medical UniversityHar ikke rekruttert ennå
-
Guangzhou Virotech Pharmaceutical Co., Ltd.Rekruttering
-
Peking University Cancer Hospital & InstituteHar ikke rekruttert ennåSmåcellet lungekarsinomKina